The apelin receptor gene, also known as APJ or angiotensin receptor-like 1, was first cloned in 1993. APJ has strong sequence homology with the angiotensin II receptor (AT1); 54% for intrans membrane domains and 31% for the entire sequence. Nevertheless, APJ does not bind with angiotensin II. In 1998, Apelin, the first endogenous ligand for APJ, was identified in bovine stomach extracts. Both apelin and APJ are widely expressed in various tissues including the heart, brain, limbs, retina, liver, lung, skin, kidney, adipose tissue, and so on [1] .
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Some of the most compelling aspects of apelin-APJ physiology are related to its effects on the cardiovascular system. Apelin is one of the most potent known inotropic agents, and low doses in mice have been shown to increase myocardial contraction and reduce cardiac load without inducing pathological hypertrophy. APJ is also involved in an apelin-independent response to mechanical stretch. Notably, genetic loss of APJ confers resistance to chronic pressure overload by markedly reducing myocardial hypertrophy and heart failure [2] .
Recently, different observations imply the possible existence of another ligand for APJ. APJ is expressed early during gastrulation and throughout the subsequent developmental stages, whereas apelin expression starts only at the end of gastrulation [3] . Apelinknockout mice are viable with a Mendelian inheritance pattern, which is different from APJ-knockout mice [4] . Moreover, APJknockout mice present different phenotypes compared with apelinknockout mice. Apelin-knockout mice have no defects in early embryonic development, which is inconsistent with the inactivation of APJ, the loss of which leads to various embryonic lethality due to growth retardation and cardiac malformations. Similar phenomenon is also found in zebrafish where knockdown of apelin protein expression does not phenocopy the loss of APJ [5] . All these studies suggested the possible existence of another unknown ligand for APJ.
Two independent studies have identified a new endogenous peptide ligand for APJ, named Elabela [6, 7] . Elabela is highly expressed during gastrulation and its knockdown in zebrafish mirrors the phenotype of loss of APJ. Human Elabela consists of three exons on chromosome 4, which generates a transcript (AK092578) annotated as a non-coding RNA. However, Chng et al. [6] revealed that this gene contains a conserved open reading frame predicted to express a conserved vertebrate protein of 54 amino acids (aa) consisting of a secretory signal and a mature 32-aa peptide named as Elabela. Elabela encodes a conserved vertebrate protein of 54 aa consisting of an N-terminal signal-peptide addressing the protein to the secretory pathway and a mature 32-aa peptide. Elabela may generate several fragments due to the presence of doublets of basic residues predicted to be cleavage sites in its peptide sequence.
In humans, Elabela transcripts are detected in embryonic stem cells, induced pluripotent stem cells, kidney, heart, and blood vessels. Through APJ, Elabela promotes angiogenesis in vitro, relaxes murine aortic blood vessels and attenuates high blood pressure in vivo. Endogenous Elabela is expressed in the kidney, especially in renal collecting duct cells. Schreiber et al. [8] overexpressed rat Elabela in the heart via AAV9 vector by a single intravenous injection. Elabela-treated animals show delayed onset of blood pressure elevation. Prior to high-salt diet, a reduction in fractional sodium and chloride excretion was observed in rats which had been given the AAV9-ELA vector. These results implied that sustained AAVElabela expression may offer a potential long-term therapy for hypertension and renal remodeling.
Moreover, Elabela is a novel hormonal peptide associated with heart development [6] , which exhibits potent cardioprotective effects in failing hearts [9] . Recently, Sato et al. [10] demonstrated that continuous infusion of Elabela significantly suppresses pressure overload-induced cardiac hypertrophy, fibrosis and impaired contractility in mice. These effects are contingent on the presence of Elabela's cognate receptor, since the cardioprotective effects of Elabela are diminished in APJ-knockout mice. Mechanistically, Elabela inhibits the expression of angiotensin-converting enzyme (ACE) in the stressed hearts, whereas it shows little effect on ACE2 expression. Down-regulation of ACE expression is correlated with the down-regulation of Forkhead box protein M1 (FoxM1) transcription factor. They further investigated the effects of Elabela on Ang II-induced cardiovascular dysfunctions. Continuous infusion of Ang II elevates blood pressure in mice, whereas co-treatment with Elabela and Ang II significantly down-regulates Ang II-induced hypertension. In addition, Elabela suppresses Ang II-induced cardiac hypertrophy, cardiac fibrosis, and fibrotic genes expression. These results demonstrated that exogenous Elabela peptide can suppress pressure overload-and Ang II-induced hypertension, cardiac hypertrophy, and fibrosis (Fig. 1) [10] .
Yang et al. [11] provided additional proof that Elabela may be of therapeutic use in pulmonary arterial hypertension (PAH). In their study, they initially use molecular dynamic simulation based on homology models of the apelin receptor to make a receptor template into which Elabela could be reliably docked. Despite the lack of obvious sequence similarity, ELA-11, one of the putative endogeous forms of ELA that preferentially activates the G protein signaling, can still dock within the binding pocket occupied by apelin-13. Furthermore, they indicated that Elabela increases cardiac contractility, ejection fraction, and cardiac output, and elicits vasodilatation in rat in vivo. Elabela can increase cardiac output owing to increased stroke volume and possibly increased heart rate. Administration of Elabela attenuates the remodeling of pulmonary vasculature and hypertrophy of right ventricular (RV) cardiomyocytes, which blunts the increase of RV systolic pressure and hypertrophy induced by monocrotaline (MCT) in this rat model of PAH. These results showed that Elabela is an endogenous agonist of the APJ, which can reduce the severity of cardiopulmonary remodeling and function in PAH (Fig. 1) [11] .
In summary, these recent results revealed that the Elabela-APJ axis may protect against pressure overload-induced heart failure and antagonize the effects of Ang II in the heart. Similarly, Elabela also plays beneficial roles in heart failure, but has distinct structure and regulation. Using Elabela peptide as a therapeutic compound could be another option to activate APJ in cardiovascular diseases. Further analyses for Elabela and apelin signaling will provide more mechanistic insights into the regulation of APJ activation in cardiovascular diseases. Figure 1 . Elabela peptide significantly suppresses pressure overload-induced cardiac hypertrophy, fibrosis, and impaired contractility in mice Exogenous Elabela peptide can also suppress Ang II-induced hypertension, cardiac hypertrophy and fibrosis. Exogenous Elabela can reduce the severity of cardiopulmonary remodeling and function in monocrotaline-induced PAH in rats. TAC, transverse aortic constriction; RVSP, right ventricular systolic pressure.
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